Practical Tips from the Judges’ Panel at the PTAB Judicial Conference
By: S. Christian Platt and Michael Lavine – Takeaways from the July 26, 2018 Judges’ Panel at the PTAB Judicial Conference hosted by the USPTO’s Silicon Valley Regional Office.
Federal Circuit: “All the Expenses” Does Not Mean “Attorneys’ Fees”
By: Gregory A. Castanias and Daniel Kazhdan – The Federal Circuit cites Jones Day’s amicus in concluding that challenging a PTAB decision in district court does not require paying PTAB’s attorneys’ fees.
Chief Judge Ruschke Presents on PTAB Fact v. Myth
By: Gasper J. LaRosa – Chief Judge Ruschke made a data driven presentation noting IPR filings are leveling off and the PTAB invalidates patents at a rate than commonly believed.
Sen. Hatch on Amendment to Incentivize Generic Drug Development
By Matt Johnson – On July 14, 2018, Senator Orrin Hatch delivered remarks to the Senate Judiciary Committee regarding the Hatch-Waxman Integrity Act of 2018.
PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation
By: J. Jason Williams and Cary Miller, Ph.D. – The PTAB considers the patentability of a method of treatment patent directed to treating multiple sclerosis using a composition found obvious in an earlier filed IPR.